AMETEK Inc (AME)

収益の仕組み

Revenue comes almost entirely from selling physical products — instruments, sensors, motors, components and metal powders — recognised when the equipment ships or is transferred to the customer, plus a smaller stream of aftermarket parts, calibration, repair and service on the installed base. Prices are set on differentiated, often engineered-to-order products rather than on commodity terms, and the company adds revenue year after year by buying niche manufacturers and folding them into its two operating groups: fiscal 2025 growth of 6.6% came from acquisitions, organic growth and favourable currency together.

セグメント別売上高

AMETEK's own description of its strategy rests on differentiated, proprietary technology sold into narrow niches: it states that its competitive position depends on developing technologically advanced products and on protecting that technology through patents and trade secrets, and it warns that failure on either count would put it at a disadvantage. Because much of the equipment is designed into a customer's process, aircraft or medical device and then qualified there, replacing it is not a simple purchasing decision. The advantage is real but bounded — the company describes strong competition across its markets and a need for continuous investment in new products just to hold position, which is why this reads as narrow rather than wide.

Demand tracks customers' capital and maintenance budgets: process plants, power producers, laboratories, semiconductor fabs and aircraft programmes order instruments when they are building, upgrading or re-qualifying, and postpone when they are not. The company itself says a number of its industries are cyclical. What softens the swing is the spread of end markets and the mix inside them — medical components, implantables and single-use surgical instruments in EMG, plus emission monitoring and aftermarket parts, calibration and repair work, behave more steadily than capital equipment; aerospace, semiconductor and general industrial orders behave less steadily. The result sits between defensive and fully cyclical rather than at either end.

主なリスク

• Cyclical end markets — The company states that a number of the industries it serves are cyclical in nature, and that an economic downturn in those markets could reduce demand and harm its results.
• International operations, tariffs and currency — With 48.2% of 2025 sales made outside the United States, AMETEK discloses exposure to trade restrictions and tariffs, changing foreign regulation, currency swings and political instability in the countries where it sells and manufactures.
• Dependence on new product development — The filing warns that failing to develop technologically advanced products on time would hurt its competitive position and future prospects, since much of its pricing power rests on that technical lead.
• Acquisition identification and integration — Growth depends in part on buying other businesses, and the company discloses the risk of not finding suitable targets, not financing them on acceptable terms, or not integrating them successfully once bought.
• Supply chain and raw material cost — Shortages of, or price increases in, raw materials and purchased components could hold back production and squeeze competitiveness, according to the company's own risk factors.
• Cybersecurity and IT disruption — AMETEK discloses that a breach of its information systems, ransomware or a cyber-attack could interrupt operations and expose sensitive company and customer data.
• Competition in served markets — The company states it faces strong competition in the markets it serves, which could limit growth and requires continuous spending on product innovation.
• Skilled workforce — Failure to hire, train and retain skilled employees is disclosed as a risk to integrating acquired businesses and to growth generally.

The filing does not give a single top-customer figure for the whole group; it discloses concentration one segment at a time, and both readings are low. Around 4% of EIG's 2025 net sales went to its five largest customers, with no single customer above 2% of that segment's sales. In EMG the five largest customers accounted for about 15% of 2025 net sales, with no single customer above 5%. So the medical and automation components side is the more concentrated of the two, and even there the exposure to any one buyer is small.